A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

Study Summary

This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM. The study is designed to follow each participant up to a maximum of 24 months.

Conditions

Indolent Systemic Mastocytosis

Interventions / Drugs

Avapritinib

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment80 participants

Primary Completion—

Lead SponsorBlueprint Medicines Corporation

Data Retrieved2026-04-11 04:08:23.597196+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.